Payment overview · 2025
General Payments
$1,065.82
58 reported records · 12 companies
Healthcare provider profile · identity verified
Preston Mcdonnell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HAZLEHURST, MS · NPI 1285863886
Verified facts
What the public records show
CMS Open Payments records show Preston Mcdonnell, M.D. received $1,065.82 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $281.51 | 26.4% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $187.19 | 17.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.75 | 14.1% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $116.55 | 10.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.48 | 9.8% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.05 | 8.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.19 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.36 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.51 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.84 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.29 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,065.82 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $187.19 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $176.24 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $149.75 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $116.55 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.69 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.05 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $83.84 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.43 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.63 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.19 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 95 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 482 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 257 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
235 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
482 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
482 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
196 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
233 | 37 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
257 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1080 | 234 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1041 | 224 |
| Gabapentin | Gabapentin | 955 | 183 |
| Pantoprazole Sodium | Pantoprazole Sodium | 782 | 142 |
| Omeprazole | Omeprazole | 698 | 159 |
| Furosemide | Furosemide | 687 | 170 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 679 | 132 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 661 | 89 |
| Meloxicam | Meloxicam | 627 | 146 |
| Potassium Chloride | Potassium Chloride | 627 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 608 | 116 |
| Metformin Hcl | Metformin Hcl | 587 | 140 |
| Escitalopram Oxalate | Escitalopram Oxalate | 536 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 527 | 107 |
| Lisinopril | Lisinopril | 520 | 106 |
| Montelukast Sodium | Montelukast Sodium | 514 | 107 |
| Losartan Potassium | Losartan Potassium | 498 | 115 |
| Jardiance | Empagliflozin | 482 | 87 |
| Trazodone Hcl | Trazodone Hcl | 456 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 452 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 102 |
| Famotidine | Famotidine | 407 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 399 | 85 |
| Alprazolam | Alprazolam | 390 | 64 |
| Spironolactone | Spironolactone | 383 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 375 | 70 |
| Eliquis | Apixaban | 371 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 365 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 350 | 90 |
| Azithromycin | Azithromycin | 343 | 271 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 330 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 298 | 68 |
| Carvedilol | Carvedilol | 282 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 275 | 64 |
| Prednisone | Prednisone | 258 | 112 |
| Ozempic | Semaglutide | 257 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 250 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 238 | 49 |
| Simvastatin | Simvastatin | 236 | 61 |
| Farxiga | Dapagliflozin Propanediol | 235 | 43 |
| Trulicity | Dulaglutide | 233 | 37 |
| Allopurinol | Allopurinol | 214 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 213 | 39 |
| Atenolol | Atenolol | 208 | 37 |
| Tramadol Hcl | Tramadol Hcl | 206 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 201 | 45 |
| Mirtazapine | Mirtazapine | 196 | 35 |
| Mounjaro | Tirzepatide | 196 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 195 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 182 | 47 |
| Methylprednisolone | Methylprednisolone | 178 | 152 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 177 | 25 |
| Doxepin Hcl | Doxepin Hcl | 173 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 172 | 32 |
| Clonazepam | Clonazepam | 172 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 171 | 27 |
| Estradiol | Estradiol | 168 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 154 | 86 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 153 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 40 |
| Buspirone Hcl | Buspirone Hcl | 150 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 145 | 23 |
| Sucralfate | Sucralfate | 142 | 29 |
| Clonidine Hcl | Clonidine Hcl | 140 | 43 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 25 |
| Sertraline Hcl | Sertraline Hcl | 137 | 31 |
| Fluconazole | Fluconazole | 135 | 64 |
| Ibuprofen | Ibuprofen | 134 | 57 |
| Linzess | Linaclotide | 134 | 29 |
| Propranolol Hcl Er | Propranolol Hcl | 133 | 23 |
| Celecoxib | Celecoxib | 128 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 128 | 14 |
| Pregabalin | Pregabalin | 120 | 32 |
| Ezetimibe | Ezetimibe | 119 | 30 |
| Metoclopramide Hcl | Metoclopramide Hcl | 119 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 118 | 20 |
| Nystatin | Nystatin | 118 | 51 |
| Temazepam | Temazepam | 118 | 24 |
| Divalproex Sodium | Divalproex Sodium | 114 | 11 |
| Bupropion Xl | Bupropion Hcl | 113 | 20 |
| Januvia | Sitagliptin Phosphate | 111 | 17 |
| Nifedipine Er | Nifedipine | 110 | 30 |
| Risperidone | Risperidone | 109 | 23 |
| Myrbetriq | Mirabegron | 106 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 105 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 105 | 23 |
| Xarelto | Rivaroxaban | 105 | 17 |
| Donepezil Hcl | Donepezil Hcl | 104 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 38 |
| Memantine Hcl | Memantine Hcl | 101 | 23 |
| Ondansetron Odt | Ondansetron | 99 | 49 |
| Lorazepam | Lorazepam | 98 | 27 |
| Entresto | Sacubitril/Valsartan | 95 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 95 | 71 |
| Gemfibrozil | Gemfibrozil | 93 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 17 |
| Megestrol Acetate | Megestrol Acetate | 89 | 31 |
| Naproxen | Naproxen | 88 | 26 |
| Glimepiride | Glimepiride | 87 | 25 |
| Aripiprazole | Aripiprazole | 86 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 12 |
| Baclofen | Baclofen | 80 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 55 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 56 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 63 |
| Finasteride | Finasteride | 78 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 19 |
| Midodrine Hcl | Midodrine Hcl | 77 | 19 |
| Glyxambi | Empagliflozin/Linagliptin | 76 | 13 |
| Novolog Flexpen | Insulin Aspart | 76 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 74 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 16 |
| Diazepam | Diazepam | 69 | 18 |
| Tradjenta | Linagliptin | 69 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Promethazine Hcl | Promethazine Hcl | 64 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 63 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 19 |
| Synthroid | Levothyroxine Sodium | 59 | 12 |
| Colchicine | Colchicine | 58 | 24 |
| Clindamycin Hcl | Clindamycin Hcl | 57 | 30 |
| Ketoconazole | Ketoconazole | 57 | 21 |
| Meclizine Hcl | Meclizine Hcl | 57 | 29 |
| Mupirocin | Mupirocin | 57 | 33 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 55 | suppressed |
| Lactulose | Lactulose | 54 | 20 |
| Valacyclovir | Valacyclovir Hcl | 54 | 19 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 18 |
| Digoxin | Digoxin | 48 | suppressed |
| Methocarbamol | Methocarbamol | 48 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 22 |
| Indomethacin | Indomethacin | 46 | 18 |
| Valsartan | Valsartan | 46 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 23 |
| Clarithromycin | Clarithromycin | 43 | 37 |
| Lovastatin | Lovastatin | 43 | 11 |
| Nitroglycerin | Nitroglycerin | 43 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 41 | 15 |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Brilinta | Ticagrelor | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Rybelsus | Semaglutide | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 35 | 27 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 34 | 29 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Dexamethasone | Dexamethasone | 33 | 32 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 31 |
| Cephalexin | Cephalexin | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 28 | 24 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 19 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Metolazone | Metolazone | 21 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Probenecid | Probenecid | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 11 |
| Clonidine | Clonidine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 11 |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,065.82 · 58 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ENTRESTO, FREESTYLE LIBRE, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, Ozempic, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error